Oligodendroglial tau filament formation in transgenic mice expressing G272V tau

Genetic evidence indicates that several mutations in tau, including G272V, are linked to frontotemporal dementia with parkinsonism. We expressed this mutation in mouse brains by combining a prion protein promoter‐driven expression system with an autoregulatory transactivator loop that resulted in high expression of human G272V tau in neurons and in oligodendrocytes. We show that G272V tau can form filaments in murine oligodendrocytes. Electron microscopy established that the filaments were either straight or had a twisted structure; these were 17–20 nm wide and had a periodicity of ≈ 75 nm. Filament formation was associated with tau phosphorylation at distinct sites, including the AT8 epitope 202/205 in vivo. Immunogold electron microscopy of sarcosyl‐extracted spinal cords from G272V transgenic mice using phosphorylation‐dependent antibodies AT8 or AT100 identified several sparsely gold‐labelled 6‐nm filaments. In the spinal cord, fibrillary inclusions were also identified by thioflavin‐S fluorescent microscopy in oligodendrocytes and motor neurons. These results establish that expression of the G272V mutation in mice causes oligodendroglial fibrillary lesions that are similar to those seen in human tauopathies.

[1]  Jürgen Götz,et al.  Tau and transgenic animal models , 2001, Brain Research Reviews.

[2]  R. Nitsch,et al.  Tau Filament Formation in Transgenic Mice Expressing P301L Tau* , 2001, The Journal of Biological Chemistry.

[3]  Wen-Lang Lin,et al.  Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein , 2000, Nature Genetics.

[4]  R. A. Crowther,et al.  Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein , 2000, Acta Neuropathologica.

[5]  Kevin K. W Wang,et al.  Calpain and caspase: can you tell the difference? , 2000, Trends in Neurosciences.

[6]  H. Braak,et al.  Filamentous Tau Pathology in Nerve Cells, Astrocytes, and Oligodendrocytes of Aged Baboons , 2000, Journal of neuropathology and experimental neurology.

[7]  H. Geerts,et al.  Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. , 1999, The American journal of pathology.

[8]  M. Hutton,et al.  FTDP‐17 tau mutations decrease the susceptibility of tau to calpain I digestion , 1999, FEBS letters.

[9]  John Q Trojanowski,et al.  Neurodegenerative Tauopathies Human Disease and Transgenic Mouse Models , 1999, Neuron.

[10]  Bin Zhang,et al.  Age-Dependent Emergence and Progression of a Tauopathy in Transgenic Mice Overexpressing the Shortest Human Tau Isoform , 1999, Neuron.

[11]  J. Trojanowski,et al.  Transgenic Models of Tauopathies and Synucleinopathies , 1999, Brain pathology.

[12]  A. Delacourte,et al.  Comparative Biochemistry of Tau in Progressive Supranuclear Palsy, Corticobasal Degeneration, FTDP‐17 and Pick's Disease , 1999, Brain pathology.

[13]  D. Dickson,et al.  Multiple System Atrophy: A Sporadic Synucleinopathy , 1999, Brain pathology.

[14]  E. Mandelkow,et al.  Tau regulates the attachment/detachment but not the speed of motors in microtubule-dependent transport of single vesicles and organelles. , 1999, Journal of cell science.

[15]  G. Varani,et al.  Structure of tau exon 10 splicing regulatory element RNA and destabilization by mutations of frontotemporal dementia and parkinsonism linked to chromosome 17. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Olivier Rascol,et al.  A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy , 1999, Acta Neuropathologica.

[17]  M. Tolnay,et al.  REVIEW: tau protein pathology in Alzheimer’s disease and related disorders , 1999, Neuropathology and applied neurobiology.

[18]  A. Grover,et al.  5′ Splice Site Mutations in tau Associated with the Inherited Dementia FTDP-17 Affect a Stem-Loop Structure That Regulates Alternative Splicing of Exon 10* , 1999, The Journal of Biological Chemistry.

[19]  P. Lantos,et al.  The definition of multiple system atrophy: a review of recent developments. , 1998, Journal of neuropathology and experimental neurology.

[20]  W. Kamphorst,et al.  Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau. , 1998, The American journal of pathology.

[21]  B. Hemmings,et al.  Delayed embryonic lethality in mice lacking protein phosphatase 2A catalytic subunit Calpha. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Goedert,et al.  Tau protein pathology in neurodegenerative diseases , 1998, Trends in Neurosciences.

[23]  A Klug,et al.  Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Ronald C. Petersen,et al.  Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.

[25]  J. Trojanowski,et al.  The Neuropathology of a Chromosome 17-Linked Autosomal Dominant Parkinsonism and Dementia (“Pallido-Ponto-Nigral Degeneration”) , 1998, Journal of neuropathology and experimental neurology.

[26]  G. Schellenberg,et al.  Tau is a candidate gene for chromosome 17 frontotemporal dementia , 1998, Annals of neurology.

[27]  M. Squier,et al.  The Neuropathology , 1998 .

[28]  H. Akiyama,et al.  Glial Tau Pathology in Neurodegenerative Diseases: Their Nature and Comparison with Neuronal Tangles , 1998, Neurobiology of Aging.

[29]  T. Iwatsubo,et al.  Somatodendritic localization of phosphorylated tau in neonatal and adult rat cerebral cortex , 1997, Neuroreport.

[30]  P. Lantos,et al.  Tau protein in the glial cytoplasmic inclusions of multiple system atrophy can be distinguished from abnormal tau in Alzheimer's disease , 1997, Neuroscience Letters.

[31]  R A Crowther,et al.  Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Crowther,et al.  Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans , 1996, Nature.

[33]  J. Ávila,et al.  Polymerization of τ into Filaments in the Presence of Heparin: The Minimal Sequence Required for τ ‐ τ Interaction , 1996 .

[34]  D. Dickson,et al.  Neuropathologic Overlap of Progressive Supranuclear Palsy, Pick's Disease and Corticobasal Degeneration , 1996, Journal of neuropathology and experimental neurology.

[35]  D. Schatz,et al.  A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[36]  P. Cohen,et al.  Molecular dissection of the paired helical filament , 1995, Neurobiology of Aging.

[37]  M. Goedert,et al.  Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. , 1995, The EMBO journal.

[38]  P. Wong,et al.  The rod domain of NF-L determines neurofilament architecture, whereas the end domains specify filament assembly and network formation , 1993, The Journal of cell biology.

[39]  N. Cairns,et al.  Tau proteins of alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms , 1992, Neuron.

[40]  M. Goedert,et al.  Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. , 1990, The EMBO journal.

[41]  A. Hirano,et al.  A COMPARATIVE STUDY OF MODIFIED BIELSCHOWSKY, BODIAN AND THIOFLAVIN S STAINS ON ALZHEIMER'S NEUROFIBRILLARY TANGLES , 1986, Neuropathology and applied neurobiology.

[42]  R. Nitsch,et al.  Distinct role of protein phosphatase 2A subunit Calpha in the regulation of E-cadherin and beta-catenin during development. , 2000, Mechanisms of development.

[43]  J. Brion,et al.  Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease. , 1999, The American journal of pathology.

[44]  M. Goedert,et al.  The tauopathies: toward an experimental animal model. , 1999, The American journal of pathology.

[45]  J. Ávila,et al.  Polymerization of tau into filaments in the presence of heparin: the minimal sequence required for tau-tau interaction. , 1996, Journal of neurochemistry.

[46]  R. Brandt,et al.  Orientation, assembly, and stability of microtubule bundles induced by a fragment of tau protein. , 1994, Cell motility and the cytoskeleton.

[47]  F. Gallyas,et al.  Silver staining of Alzheimer's neurofibrillary changes by means of physical development. , 1971, Acta morphologica Academiae Scientiarum Hungaricae.